Effects of physical exercise on markers of aging in physically inactive adults approaching later life Not Applicable
Conditions
Interventions
Participants are randomized 1:1 either to the control group or the exercise intervention group after all the baseline measurements. A computerized randomization sequence is used, stratified by sex and
Sponsors
Folkhälsans Forskningscentrum
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Non-smoker or quit smoking =1 year ago 2. Age 50–70 years 3. Body mass index =25 and <32 kg/m² 4. Passed medical examination to participate 5. Not following a regular physical exercise regime or having a physically active lifestyle 6. Finnish or Swedish as a first language
Exclusion criteria
Exclusion criteria: 1. Pre-existing, or history of major cardiovascular disease (coronary artery disease, heart failure, stroke, peripheral vascular disease) 2. Type 1 diabetes 3. Type 2 diabetes 4. Cancer 5. Neurodegenerative disease (e.g. Alzheimer’s disease, Parkinson’s disease) 6. Rheumatoid arthritis 7. Chronic obstructive pulmonary disease (COPD) 8. Diagnosed moderate or severe depression 9. Use of metformin or other hyperglycemia medication 10. Scheduled to undergo major surgery in the next 6 months 11. Findings detected during spiroergometry that limit safe participation to the intervention according to the Finnish national guidelines
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Phenotypic age measured using a fasting blood sample as a linear combination of chronological age and nine multisystem clinical chemistry biomarkers at baseline and 24 weeks 2. Phenotypic age acceleration measured using a fasting blood sample as a residual of phenotypic age after accounting for chronological age at baseline and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. (Relative) leucocyte telomere length is measured from whole blood leukocyte DNA using quantitative real-time polymerase chain reaction at baseline and 24 weeks 2. DNA methylation is measured from blood and saliva samples using techniques based on methylation arrays to compute b (% methylation) values for each CpG site at baseline and 24 weeks 3. Epigenetic clocks are measured from blood and buccal swab samples using the methylation information at baseline and 24 weeks (updated 04/05/2022, previously: Epigenetic clocks are measured from blood and saliva samples using the methylation information at baseline and 24 weeks) 4. Mitochondrial function is measured using near-infrared spectroscopy (NIRS) and markers of mitochondrial function from fasting blood samples at baseline and 24 weeks 5. Inflammatory markers (CRP, hs-CRP) are measured using fasting blood samples at baseline and 24 weeks 6. Lipid (total cholesterol, HDL-cholesterol, LDL-cholesterol, and triglycerides) and glucose (fasting plasma glucose, fasting plasma insulin, and hemoglobin A1c) metabolism markers are measured using fasting blood samples and oral glucose tolerance test at baseline and 24 weeks. 7. Metabolomics measured with nuclear magnetic resonance (MNR) from fasting blood samples at baseline and 24 weeks 8. Gut microbiota are measured from stool samples with techniques based on the 16S-rRNA gene sequencing and separately Short Chain Fatty Acids (SCFA) content is determined from stool samples at baseline and 24 weeks 9. Advanced glycation end products (AGE) are measured using the AGE reader as skin autofluorescence at baseline and 24 weeks. 10. Body composition (lean body mass, fat mass, fat%) is measured using bioimpedance and anthropometrics (height, weight, body mass index, waist and hip circumference) at baseline and 24 weeks 11. Muscle strength is measured using the grip strength test, the upper body dynamic strength test and the repetitive squat test for the lower body at baseline and 24 | — |
Countries
Finland
Contacts
Public ContactNiko Wasenius
Outcome results
None listed